Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$8.06M+74.7%-$31.86M-106%-$15.45M-14.0%-$13.55M+40.9%-$22.93M-34.4%
$113K-13.1%$130K-6.5%$139K-0.7%$140K+0.7%$139K-5.4%
$2.32M+68.5%$1.38M-50.5%$2.78M+47.4%$1.88M+18.7%$1.59M-34.0%
-$14.81M-74.8%-$8.47M+33.0%-$12.65M-59.8%-$7.91M+66.2%-$23.4M-261%
$52K-38.8%$85K-63.8%$235K+120%$107K-20.7%$135K+800%
-$52K+38.8%-$85K+63.8%-$235K-120%-$107K+20.7%-$135K-800%
$8K$6K+4.3%
$4.42M+570%$660K-99.2%$81.41M$0-100%$20.65M+13,050%
-$10.44M$68.53M+944%-$8.12M-181%-$2.89M
-$14.86M-73.7%-$8.55M+33.6%-$12.88M-60.6%-$8.02M+65.9%-$23.54M-262%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Aquestive Therapeutics, Inc. generate?
Aquestive Therapeutics, Inc. (AQST) generated -$43.8M in operating cash flow over the trailing twelve months.
What is Aquestive Therapeutics, Inc.'s free cash flow?
After $479.0K of capital expenditures, Aquestive Therapeutics, Inc.'s free cash flow was -$44.3M over the trailing twelve months, up 9.6% year over year.
Where does Aquestive Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.